Helsinki, Finland – Nanoform Finland Plc, the medicine performance-enhancing company, today announced new preclinical data investigating Nanoformed A1AT in the treatment of alpha-1 antitrypsin (AAT) deficiency to be presented at the 16th Global Drug Delivery & Formulation Summit (DDF) in Berlin, Germany, on June 3, 2025. The data were obtained in a non-clinical proof-of-concept study conducted in collaboration between Nanoform and Takeda.

Alpha-1 antitrypsin (AAT) deficiency is an inherited genetic disorder that increases the risk of developing lung diseases including emphysema. Its treatment currently consists of weekly intravenous infusions of plasma-derived human AAT, which can be inconvenient and burdensome for the patient.

The presentation entitled, “A Novel Nanoformed Presentation of AAT for the Treatment of Pulmonary Emphysema in AAT Deficient Patients,” will share results from the study, which investigated Nanoformed A1AT, a respirable dry powder for inhalation, as an alternative administration strategy for an AAT replacement therapy, based on a novel solidification platform from Nanoform.

“This exemplifies the applicability of Nanoform technology to deliver value to biologic formulations and, ultimately, in making better medicines for patients”, commented Prof. Edward Haeggstrom, Nanoform CEO.

Comparison of other methods such as spray drying showed that the nanoformed particulate material could deposit significantly higher amounts of AAT within the alveolar system. After optimizing the formulation, a PK study in mice including evaluation of biodistribution was executed.  

The 16th Global Drug Delivery & Formulation Summit runs from June 2-4, 2025 (https://ddfevent.com/2025/en/page/home) at the Maritim Proarte Hotel, Berlin.

For more information on the summit visit: nanoform.com/events.

For further information, please contact:

Christian Jones, Chief Commercial Officer
Christian.jones@nanoform.com
+44 (0)7804 474 771

Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 (0)7686 650 11

About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 (0)73 856 42 65, certifiedadviser@carnegie.se. For more information, please visit www.nanoform.com.

Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.